Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis.


Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
04 2020
Historique:
received: 15 01 2019
revised: 01 10 2019
accepted: 03 10 2019
pubmed: 6 12 2019
medline: 11 5 2021
entrez: 6 12 2019
Statut: ppublish

Résumé

Induced sputum (IS) allows to measure mediators of asthmatic inflammation in bronchial secretions. NSAID-exacerbated respiratory disease (NERD) is recognized as a distinct asthma phenotype, usually with a severe course, eosinophilic airway inflammation, and increased production of pro-inflammatory eicosanoids. A more insightful analysis of NERD patients has shown this phenotype to be nonhomogeneous. We aimed to identify possible subphenotypes in a cohort of NERD patients with the means of latent class analysis (LCA). A total of 95 asthma patients with aspirin hypersensitivity underwent sputum induction. High-performance liquid chromatography or gas chromatography coupled with mass spectrometry was used to profile eicosanoids in induced sputum supernatant (ISS). Sixteen variables covering clinical characteristics, IS inflammatory cells, and eicosanoids were considered in the LCA. Three classes (subphenotypes) were distinguished within the NERD cohort. Class 1 subjects had mild-to-moderate asthma, an almost equal distribution of inflammatory cell patterns, the lowest concentrations of eicosanoids, and logLTE LCA revealed three distinct NERD subphenotypes. Our results support a more complex pathobiology of aspirin hypersensitivity. Considering NERD heterogeneity, the relationship between inflammatory pathways and clinical manifestations of asthma may lead to more individualized treatment in difficult to treat patients in the future.

Sections du résumé

BACKGROUND
Induced sputum (IS) allows to measure mediators of asthmatic inflammation in bronchial secretions. NSAID-exacerbated respiratory disease (NERD) is recognized as a distinct asthma phenotype, usually with a severe course, eosinophilic airway inflammation, and increased production of pro-inflammatory eicosanoids. A more insightful analysis of NERD patients has shown this phenotype to be nonhomogeneous.
OBJECTIVE
We aimed to identify possible subphenotypes in a cohort of NERD patients with the means of latent class analysis (LCA).
METHODS
A total of 95 asthma patients with aspirin hypersensitivity underwent sputum induction. High-performance liquid chromatography or gas chromatography coupled with mass spectrometry was used to profile eicosanoids in induced sputum supernatant (ISS). Sixteen variables covering clinical characteristics, IS inflammatory cells, and eicosanoids were considered in the LCA.
RESULTS
Three classes (subphenotypes) were distinguished within the NERD cohort. Class 1 subjects had mild-to-moderate asthma, an almost equal distribution of inflammatory cell patterns, the lowest concentrations of eicosanoids, and logLTE
CONCLUSIONS
LCA revealed three distinct NERD subphenotypes. Our results support a more complex pathobiology of aspirin hypersensitivity. Considering NERD heterogeneity, the relationship between inflammatory pathways and clinical manifestations of asthma may lead to more individualized treatment in difficult to treat patients in the future.

Identifiants

pubmed: 31803947
doi: 10.1111/all.14141
pmc: PMC7216982
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Leukotriene E4 75715-89-8
Aspirin R16CO5Y76E

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

831-840

Informations de copyright

© 2019 The Authors. Allergy published by John Wiley & Sons Ltd.

Références

Allergy. 2014 Nov;69(11):1550-9
pubmed: 25123806
J Allergy Clin Immunol. 2018 Jan;141(1):442-445
pubmed: 28987809
Ann Allergy Asthma Immunol. 2010 Jun;104(6):464-70
pubmed: 20568377
Allergy Asthma Immunol Res. 2019 May;11(3):320-329
pubmed: 30912322
J Allergy Clin Immunol. 2004 Jan;113(1):101-8
pubmed: 14713914
Allergy. 2007 Oct;62(10):1111-8
pubmed: 17521312
Clin Exp Allergy. 2010 Jan;40(1):85-93
pubmed: 19895589
Curr Mol Med. 2008 Aug;8(5):335-49
pubmed: 18691060
Allergy. 2019 Jan;74(1):28-39
pubmed: 30216468
Eur Respir J Suppl. 2002 Sep;37:1s-2s
pubmed: 12361359
Asthma Res Pract. 2018 Dec 21;4:10
pubmed: 30598830
J Allergy Clin Immunol. 2017 Jul;140(1):101-108.e3
pubmed: 28279492
J Allergy Clin Immunol. 2015 Jul;136(1):59-68.e14
pubmed: 25617223
Am J Respir Crit Care Med. 2013 Aug 15;188(4):432-9
pubmed: 23805875
Blood. 2012 Apr 19;119(16):3790-8
pubmed: 22262771
Br J Pharmacol. 2006 Apr;147(7):707-13
pubmed: 16432506
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
N Engl J Med. 2018 Sep 13;379(11):1060-1070
pubmed: 30207919
Annu Rev Pathol. 2015;10:511-45
pubmed: 25423350
Allergy. 2020 Apr;75(4):831-840
pubmed: 31803947
Respir Res. 2012 Sep 19;13:78
pubmed: 22989372
Am J Rhinol Allergy. 2016 Nov 1;30(6):407-413
pubmed: 28124651
J Asthma Allergy. 2016 Mar 10;9:37-43
pubmed: 27022293
Nat Med. 2012 May 04;18(5):716-25
pubmed: 22561835
Allergy Asthma Proc. 2018 Jan 1;39(1):1-2
pubmed: 29279053
J Exp Med. 2001 Jan 1;193(1):123-33
pubmed: 11136826
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jul 1;878(21):1796-800
pubmed: 20627827
Allergy Asthma Proc. 2007 Nov-Dec;28(6):706-10
pubmed: 18201436
J Allergy Clin Immunol. 2015 Mar;135(3):676-81.e1
pubmed: 25282015
Clin Exp Allergy. 2015 Dec;45(12):1779-89
pubmed: 26449970
J Allergy Clin Immunol. 2014 Jan;133(1):98-103.e1-6
pubmed: 23993879
F1000Res. 2019 Apr 26;8:
pubmed: 31069060
Clin Immunol. 2014 Nov;155(1):126-35
pubmed: 25236785
Am J Respir Crit Care Med. 2005 Oct 15;172(8):972-9
pubmed: 16040786
Am J Rhinol Allergy. 2018 Jan 1;32(1):7-11
pubmed: 29336282
Thorax. 2008 Dec;63(12):1076-82
pubmed: 18757457
Physiol Rev. 2018 Jul 1;98(3):1335-1370
pubmed: 29717929
Allergy Asthma Immunol Res. 2019 May;11(3):381-393
pubmed: 30912327
J Allergy Clin Immunol. 2015 Jan;135(1):245-52
pubmed: 25218285
Thorax. 2010 May;65(5):384-90
pubmed: 19996343

Auteurs

Natalia Celejewska-Wójcik (N)

II Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.

Krzysztof Wójcik (K)

II Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.

Maria Ignacak-Popiel (M)

II Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.

Adam Ćmiel (A)

Department of Applied Mathematics, AGH University of Science and Technology, Cracow, Poland.

Katarzyna Tyrak (K)

II Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.

Anna Gielicz (A)

II Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.

Aleksander Kania (A)

II Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.

Paweł Nastałek (P)

II Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.

Marek Sanak (M)

II Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.

Lucyna Mastalerz (L)

II Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH